Advanced glycosylation end products in diabetic renal and vascular disease
- PMID: 7503061
- DOI: 10.1016/0272-6386(95)90051-9
Advanced glycosylation end products in diabetic renal and vascular disease
Abstract
An increasing body of experimental data supports the important, etiologic role of advanced glycosylation end products (AGEs) in the development of the renal and vascular complications of diabetes. Advanced glycosylation end products arise from glucose-derived Amadori products and act to increase vascular permeability, enhance protein and lipoprotein deposition, inactivate nitric oxide, and promote matrix protein synthesis and glomerular sclerosis. Loss of normal renal function increases the level of circulating plasma AGEs and contributes markedly to their ultimate tissue toxicity. Aminoguanidine, a recently developed pharmacologic inhibitor of advanced glycosylation, is presently undergoing phase II/III clinical trials in diabetic nephropathy and may offer a specific therapeutic modality for diminishing the formation and toxicity of AGEs.
Similar articles
-
Expression of receptors for advanced glycation end-products in occlusive vascular and renal disease.Nephrol Dial Transplant. 1996;11 Suppl 5:87-90. doi: 10.1093/ndt/11.supp5.87. Nephrol Dial Transplant. 1996. PMID: 9044315 Review.
-
What is the effect of hyperglycemia on atherogenesis and can it be reversed by aminoguanidine?Diabetes Res Clin Pract. 1996 Feb;30 Suppl:123-30. doi: 10.1016/s0168-8227(96)80048-9. Diabetes Res Clin Pract. 1996. PMID: 8964186 Review.
-
Advanced glycation end products.Contrib Nephrol. 2011;170:66-74. doi: 10.1159/000324945. Epub 2011 Jun 9. Contrib Nephrol. 2011. PMID: 21659759 Review.
-
[The role of advanced glycation end-products (AGEs) in the development of vascular diabetic complications].Arq Bras Endocrinol Metabol. 2008 Aug;52(6):940-50. doi: 10.1590/s0004-27302008000600005. Arq Bras Endocrinol Metabol. 2008. PMID: 18820805 Review. Portuguese.
-
Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors.Diabetes. 1996 Jul;45 Suppl 3:S65-6. doi: 10.2337/diab.45.3.s65. Diabetes. 1996. PMID: 8674896 Review.
Cited by
-
Mannan-Binding Lectin Is Associated with Inflammation and Kidney Damage in a Mouse Model of Type 2 Diabetes.Int J Mol Sci. 2024 Jun 29;25(13):7204. doi: 10.3390/ijms25137204. Int J Mol Sci. 2024. PMID: 39000309 Free PMC article.
-
Progress and application of adipose-derived stem cells in the treatment of diabetes and its complications.Stem Cell Res Ther. 2024 Jan 2;15(1):3. doi: 10.1186/s13287-023-03620-0. Stem Cell Res Ther. 2024. PMID: 38167106 Free PMC article. Review.
-
Recent progress in bone-repair strategies in diabetic conditions.Mater Today Bio. 2023 Oct 20;23:100835. doi: 10.1016/j.mtbio.2023.100835. eCollection 2023 Dec. Mater Today Bio. 2023. PMID: 37928253 Free PMC article. Review.
-
Fractures and dislocations of the foot and ankle in people with diabetes: a literature review.Ther Adv Endocrinol Metab. 2023 Jun 3;14:20420188231163794. doi: 10.1177/20420188231163794. eCollection 2023. Ther Adv Endocrinol Metab. 2023. PMID: 37323164 Free PMC article. Review.
-
Accelerated AGEing: The Impact of Advanced Glycation End Products on the Prognosis of Chronic Kidney Disease.Antioxidants (Basel). 2023 Feb 26;12(3):584. doi: 10.3390/antiox12030584. Antioxidants (Basel). 2023. PMID: 36978832 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
